Epidemiology
- the geographical regions most frequently studied for disease prevalence include Europe and the USA. In Europe, estimates derived from self-reporting of disease
within large cohort or population samples range from 1·0% to 2·1%, whereas estimates based on diagnosis codes range from 0·09% to 0·51%. (1) - HS occurs more commonly in females (a female to male ratio of approximately 3:1) (2,3)
- it does not start before puberty and hormonal factors are thought to play a role. The average age of onset is 21 years (4)
- patients first enter hospital settings at the age of 38y (3)
Reference:
- Sabat R et al. Hidradenitis suppurative. Lancet 2025; 405: 420–38
- Ingram JR, Jenkins-Jones S, Knipe DW, et al. Population-based clinical practice research datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. Br J Dermatol. 2018 Apr;178(4):917-24
- Hasan S B, Harris C, Collier F. Hidradenitis suppurativa BMJ 2022; 379 :e068383 doi:10.1136/bmj-2021-068383
- Collier F, Smith RC, Morton CA; Diagnosis and management of hidradenitis suppurativa. BMJ. 2013 Apr 23;346:f2121
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.